Has the Belgian Healthcare Sector valuation changed over the past few years?

Investors are pessimistic on the Belgian Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 28.5x which is lower than its 3-year average PE of 228x. The industry is trading close to its 3-year average PS ratio of 6.8x.

Which industries have driven the changes within the Belgian Healthcare sector?

Investors are most optimistic about the Biotech industry which is trading above its 3-year average PE ratio. Analysts are expecting annual earnings growth of 26.8%, which is lower than the prior year's growth of 33.9% per year.

Belgian (BEL20) Healthcare Sector Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 16 Sep 2026	€104.2b	€16.0b	€3.7b	18.2x	28.5x	6.5x
Fri, 14 Aug 2026	€99.7b	€16.0b	€3.7b	19x	27x	6.3x
Sun, 12 Jul 2026	€105.0b	€14.6b	€2.9b	29x	36.4x	7.2x
Tue, 09 Jun 2026	€110.1b	€14.6b	€2.9b	31.9x	38.4x	7.5x
Thu, 07 May 2026	€99.6b	€14.1b	€2.7b	28.8x	37.5x	7.1x
Sat, 04 Apr 2026	€102.8b	€14.2b	€2.7b	30.7x	38.6x	7.3x
Mon, 02 Mar 2026	€101.2b	€14.0b	€2.6b	28.7x	38.2x	7.2x
Wed, 28 Jan 2026	€107.3b	€12.6b	€2.6b	30.6x	41.2x	8.5x
Fri, 26 Dec 2025	€100.6b	€12.7b	€2.6b	27.3x	38.3x	8x
Sun, 23 Nov 2025	€104.7b	€12.7b	€2.7b	26x	39.4x	8.2x
Tue, 21 Oct 2025	€105.9b	€12.2b	€2.4b	27.8x	43.5x	8.7x
Thu, 18 Sep 2025	€86.8b	€12.2b	€2.4b	32.2x	35.9x	7.1x
Sat, 16 Aug 2025	€80.1b	€12.1b	€2.4b	33.7x	33.4x	6.6x
Mon, 14 Jul 2025	€70.7b	€11.0b	€1.9b	34.2x	36.4x	6.4x
Wed, 11 Jun 2025	€70.9b	€11.0b	€2.0b	33.5x	36.1x	6.4x
Fri, 09 May 2025	€66.5b	€10.7b	€1.8b	37.7x	37.2x	6.2x
Sun, 06 Apr 2025	€68.0b	€10.7b	€1.8b	37.9x	37.7x	6.3x
Tue, 04 Mar 2025	€82.3b	€10.5b	€1.1b	41.3x	75x	7.8x
Thu, 30 Jan 2025	€83.4b	€9.8b	€270.1m	63.2x	309x	8.6x
Sat, 28 Dec 2024	€91.7b	€9.8b	€270.1m	60.2x	339.3x	9.4x
Mon, 25 Nov 2024	€77.8b	€9.8b	€270.1m	59.2x	287.9x	8x
Wed, 23 Oct 2024	€72.3b	€9.5b	€129.9m	61x	556.3x	7.6x
Fri, 20 Sep 2024	€67.4b	€9.4b	€134.4m	57.7x	501.6x	7.2x
Sun, 18 Aug 2024	€65.2b	€9.4b	€61.2m	55.2x	1065.6x	6.9x
Tue, 16 Jul 2024	€60.4b	€8.9b	€39.5m	57.3x	1530.8x	6.8x
Thu, 13 Jun 2024	€53.2b	€8.9b	€36.9m	54.5x	1440x	6x
Sat, 11 May 2024	€51.0b	€8.9b	€30.8m	48.4x	1654.9x	5.7x
Mon, 08 Apr 2024	€49.7b	€8.7b	€63.0m	46.3x	789.5x	5.7x
Wed, 06 Mar 2024	€47.6b	€9.4b	-€127,148,925.00	43.7x	-374.6x	5.1x
Fri, 02 Feb 2024	€43.2b	€9.1b	-€126,241,713.00	39.4x	-342.2x	4.7x
Sun, 31 Dec 2023	€40.9b	€9.1b	-€122,911,856.00	37.5x	-333.1x	4.5x
Tue, 28 Nov 2023	€45.4b	€9.1b	-€121,134,232.00	33.2x	-374.9x	5x
Thu, 26 Oct 2023	€45.4b	€9.0b	-€302,763,688.00	33x	-150.1x	5.1x
Sat, 23 Sep 2023	€49.3b	€9.0b	-€364,014,035.00	35.2x	-135.5x	5.5x


BE Market	-0.41%
Healthcare	0.22%
Medical Equipment	1.39%
Pharma	1.36%
Healthcare Services	0.69%
Life Sciences	0%	0
Biotech	-0.81%
Healthtech	-6.99%

Company	Last Price	7D	1Y	Valuation
UCB UCB	€206.10	0.7% +€286.0m	1.5%	PE17.9x
TUB Financière de Tubize	€177.40	1.0% +€75.7m	7.3%	PE80.2x
FAGR Fagron	€22.05	3.0% +€47.7m	12.6%	PE17.6x
NYXH Nyxoah	€1.38	3.3% +€4.4m	-65.1%	PS6.4x
ALEMS European Medical Solutions	€4.24	8.7% +€1.4m	-8.8%	PE8.7x

Announcement • Sep 09

UCB Receives U.S. FDA Breakthrough Therapy Designation For CIMZIA (Certolizumab Pegol) In Pregnant Women With Antiphospholipid Syndrome

UCB announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to CIMZIA (certolizumab pegol) for the prevention of placenta-mediated adverse pregnancy outcomes in pregnant women who have antiphospholipid syndrome (APS) and are positive for lupus anticoagulant (LA). These patients were considered at risk due to prior obstetric and blood clotting (thrombotic) events. The designation is supported by preliminary clinical evidence from the IMPACT study, and recognizes the potential of CIMZIA to address a significant unmet medical need in an area where there are currently no FDA-approved therapies for the prevention of adverse pregnancy outcomes in patients with APS. A BTD is granted to medicines intended to treat a serious or life-threatening condition when preliminary clinical evidence indicates the therapy may demonstrate substantial improvement over available treatments on one or more clinically significant endpoints. The designation is designed to facilitate development and expedite the FDA review of promising new therapies. APS is a rare autoimmune disorder associated with increased risk of blood clots and serious pregnancy complications, including recurrent pregnancy loss in the first trimester, pre-eclampsia, placental insufficiency, fetal growth restriction, preterm birth, and stillbirth. Despite the significant burden of the condition, patients are typically managed with low-dose aspirin and heparin, highlighting a substantial unmet medical need. Results from the IMPACT study demonstrated the potential of CIMZIA to prevent adverse pregnancy outcomes in women with APS considered high risk due to LA positivity and prior obstetric or thrombotic manifestations of the disease. The findings add to growing evidence implicating tumor necrosis factor (TNF)-mediated inflammation in APS-related pregnancy complications. The designation builds on the FDA's recent Orphan Drug Designation for CIMZIA for the prevention of placenta-mediated adverse pregnancy outcomes in pregnant patients with APS. CIMZIA is not currently approved in pregnant women with APS, and the safety and efficacy have not been established for this use. Antiphospholipid syndrome (APS) is a rare and serious autoimmune condition that mainly affects women of childbearing age (WoCBA), characterized by the presence of antiphospholipid antibodies, which can cause repeated blood clots in arteries and veins. The condition is associated with serious pregnancy complications, including recurrent pregnancy loss in the first trimester, pre-eclampsia, placental insufficiency, fetal growth restriction, preterm birth, stillbirth, and a range of serious placenta-mediated adverse pregnancy outcomes. Current standard-of-care treatment typically includes low-dose aspirin and heparin during pregnancy; however, no therapies are currently approved specifically for the prevention of adverse pregnancy outcomes in this patient population. IMPACT (IMProve Pregnancy in APS with Certolizumab Therapy) was an investigator-sponsored study evaluating certolizumab pegol in pregnant women with APS at high risk of adverse pregnancy outcomes. Published results demonstrated the potential of certolizumab pegol to prevent adverse pregnancy outcomes in this high-risk population. Breakthrough Therapy Designation (BTD) is an FDA program intended to expedite the development and review of medicines for serious or life-threatening conditions. The designation is granted when preliminary clinical evidence indicates that a therapy may demonstrate substantial improvement over available treatment options on one or more clinically significant endpoints. BTD provides opportunities for more intensive FDA guidance and organizational commitment to support efficient development and review, and is not a label indication approval. Orphan Drug Designation is granted by the FDA to medicines intended for the treatment, prevention, or diagnosis of rare diseases or conditions affecting fewer than 200,000 people in the United States. The designation is designed to encourage the development of therapies for rare diseases and may provide incentives to sponsors, including development support and certain regulatory and commercial benefits. The designation does not constitute marketing approval or determine a medicine's safety or efficacy. CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease (CD) and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy; Treatment of adults with moderately to severely active rheumatoid arthritis (RA); Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older; Treatment of adult patients with active psoriatic arthritis (PsA); Treatment of adults with active ankylosing spondylitis (AS); Treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation; Treatment of adults with moderate-to-severe plaque psoriasis (PSO) who are candidates for systemic therapy or phototherapy. Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria. Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue CIMZIA if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before CIMZIA use and during therapy. Initiate treatment for latent TB prior to CIMZIA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease.

Belgian (BEL20) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

New minor risk - Share price stability

UCB Receives U.S. FDA Breakthrough Therapy Designation For CIMZIA (Certolizumab Pegol) In Pregnant Women With Antiphospholipid Syndrome

ARGX: Myositis Regulatory Outcomes Will Challenge Optimistic Immunology Franchise Expectations

Nyxoah Implants First Patient in Breathe U.S. Post-Approval Study of Genio System

Fiona Lam officially assumed the role of Group CFO at Proximus on September 1, 2026.

Proton Therapy And Radiopharma Expansion Will Drive Stronger Long-Term Prospects

Investor sentiment deteriorates as stock falls 15%

Fagron NV to Report First Half, 2027 Results on Jul 29, 2027

Hyloris Pharmaceuticals SA to Report Fiscal Year 2026 Results on Apr 30, 2027

Celyad Oncology SA announced that it expects to receive €0.5 million in funding from Fortress Investment Group LLC

New minor risk - Share price stability

Oxurion NV to Report Fiscal Year 2026 Results on Apr 02, 2027